Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SHC
Strong BuyPremium GrowerFLAGSotera Health Company · Healthcare · United States · $5.5B · Avg Vol: $45M/d
Insufficient evidence for a screen-pass. Sotera Health Company: fails the quant gate on value (Q61/V37/M79; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
COMPANY DESCRIPTION
Sotera Health Company is a leading global provider of mission-critical sterilization and lab testing services for the medical device, pharmaceutical, and food industries. The company ensures product safety and integrity through its specialized sterilization and analytical services, leveraging extensive regulatory expertise and a global network of facilities. Its indispensable role in the healthcare supply chain, combined with high barriers to entry, provides a significant and defensible market position.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.0B | 1.1B | 1.2B | 5.1% | 1.2B | 1.2B | 1.3B | 6.5% |
| EPS | -0.83 | 0.18 | 0.16 | 0.27 | 22.5% | 0.57 | 0.31 | 0.34 | 11.8% |
| Shares | 282.4M | 282.8M | 283.5M | 284.4M | +0.7% | 285.4M | — | — | — |
| Debt | 2.0B | 2.3B | 2.4B | 2.3B | 3.8% | 2.3B | — | — | — |
| Equity | 350.2M | 443.7M | 404.9M | 606.0M | 20.1% | — | — | — | — |
| Op CF | 278.0M | -147.7M | 224.2M | 287.2M | 1.1% | 292.2M | — | — | — |
| Inv CF | -181.9M | -214.9M | -179.0M | -135.1M | — | — | — | — | — |
| Fin CF | 197.8M | 266.0M | -50.6M | -100.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SHC | Sotera Health Company(you) | $5.5B | 81 | Strong Buy |
| VCYT | Veracyte, Inc. | $3.5B | 80 | Strong Buy |
| CDNA | CareDx, Inc. | $2.6B | 75 | Buy |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| BLLN | BillionToOne, Inc. | $4.4B | 61 | Hold |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| LH | Labcorp Holdings Inc. | $27.2B | 83 | Strong Buy |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.3%